Specialty code 183500000X · Charlotte, NC
NPI
1922383751
Since 2011
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
200 Hawthorne Ln
Charlotte, NC, 28204
Phone (704) 316-4610
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$9.0M
6,965 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Cindy S Kennedy prescribed most often to Medicare patients was Eliquis (Apixaban), with 2,569 prescriptions and refills. In total Cindy S Kennedy wrote 6,965 Medicare prescriptions that cost $9.0M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-10-13.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Eliquis Apixaban | 2,569 | 6,994 | 851 | $4.0M |
| Xarelto Rivaroxaban | 1,585 | 4,551 | 473 | $2.5M |
| Repatha Sureclick Evolocumab | 1,449 | 2,124 | 247 | $1.2M |
| Jardiance Empagliflozin | 327 | 952 | 138 | $545K |
| Praluent Pen Alirocumab | 242 | 392 | 49 | $196K |
| Farxiga Dapagliflozin Propanediol | 129 | 368 | 50 | $204K |
| Rosuvastatin Calcium Generic | 66 | 188 | 31 | $530 |
| Ezetimibe Generic | 61 | 164 | 22 | $791 |
| Symbicort Budesonide/Formoterol Fumarate | 39 | 97 | 12 | $21K |
| Repatha Syringe Evolocumab | 39 | 50 | Under 11 | $28K |
| Atorvastatin Calcium Generic | 37 | 101 | 14 | $371 |
| Dofetilide Generic | 34 | 102 | 11 | $9,055 |
| Entresto Sacubitril/Valsartan | 33 | 88 | 23 | $57K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 28 | 76 | 12 | $47K |
| Metoprolol Succinate Generic | 27 | 79 | Under 11 | $309 |
Brand drugs: 6,604 claims; generic drugs: 361 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Cindy S Kennedy were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.